SF3B1 mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemia

  • Sci Adv. 2024 Mar 22;10(12):eadl4018. doi: 10.1126/sciadv.adl4018.
Céline Moison  1 Deanne Gracias  1 Julie Schmitt  1 Simon Girard  1 Jean-François Spinella  1 Simon Fortier  1 Isabel Boivin  1 Rodrigo Mendoza-Sanchez  1 Bounkham Thavonekham  1 Tara MacRae  1 Nadine Mayotte  1 Eric Bonneil  1 Mark Wittman  2 James Carmichael  2 Réjean Ruel  1 Pierre Thibault  1  3 Josée Hébert  1  4  5 Anne Marinier  1  3 Guy Sauvageau  1  4  5
Affiliations
  • 1. Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada.
  • 2. Research and Development, Bristol Myers Squibb Company, Cambridge, MA, USA.
  • 3. Department of Chemistry, Université de Montréal, Montréal, Canada.
  • 4. Division of Hematology-Oncology and Quebec Leukemia Cell Bank, Maisonneuve-Rosemont Hospital, Montréal, Canada.
  • 5. Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, Canada.
Abstract

In a phenotypical screen of 56 acute myeloid leukemia (AML) patient samples and using a library of 10,000 compounds, we identified a hit with increased sensitivity toward SF3B1-mutated and adverse risk AMLs. Through structure-activity relationship studies, this hit was optimized into a potent, specific, and nongenotoxic molecule called UM4118. We demonstrated that UM4118 acts as a copper ionophore that initiates a mitochondrial-based noncanonical form of cell death known as Cuproptosis. CRISPR-Cas9 loss-of-function screen further revealed that iron-sulfur cluster (ISC) deficiency enhances copper-mediated cell death. Specifically, we found that loss of the mitochondrial ISC transporter ABCB7 is synthetic lethal to UM4118. ABCB7 is misspliced and down-regulated in SF3B1-mutated leukemia, creating a vulnerability to copper ionophores. Accordingly, ABCB7 overexpression partially rescued SF3B1-mutated cells to copper overload. Together, our work provides mechanistic insights that link ISC deficiency to Cuproptosis, as exemplified by the high sensitivity of SF3B1-mutated AMLs. We thus propose SF3B1 mutations as a biomarker for future copper ionophore-based therapies.

Products